
Axonics shares rise as Needham improves advice (NASDAQ:AXNX)
Mothballs/iStock via Getty Images MedTech Axonics Company Stock (NASDAQ: AXNX) rose premarket on Friday after Needham upgraded it to Buy from Hold with a target of $71 per share, arguing that the company’s 2023 revenue forecast appeared “conservative.” Axonic (AXNX), a developer of minimally invasive products for bladder and bowel dysfunction, expects to report revenue…